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ABSTRACT
Fabry disease is an inherited lysosomal disease in which defects in the GLA gene lead to a-galactosidase-A deficiency,
and accumulation of glycosphingolipids, including lyso-Gb3, a podocyte stressor. Therapy is available as enzyme
replacement therapy and, for some patients, the chaperone migalastat. A key decision is when to start therapy, given
its costs and potential impact on some aspects of quality of life. The decision is especially difficult in otherwise
asymptomatic patients. A delayed start of therapy may allow kidney injury to progress subclinically up to the
development of irreversible lesions. Non-invasive tools to monitor subclinical kidney injury are needed. One such tool
may be assessment of podocyturia. In this issue of CKJ, [Trimarchi H, Canzonieri R, Costales-Collaguazo C et al. Early
decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes. Clin Kidney J 2019; doi.org/10.1093/ckj/
sfy053] report on podocyturia assessment in Fabry nephropathy. Specifically, they report that podocalyxin may be lost
from detached urinary podocytes.
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Fabry disease is a hereditary metabolic disorder characterized
by accumulation of glycosphingolipids that leads to chronic kid-
ney disease (CKD), heart disease and stroke, among others [1].
Fabry nephropathy is one of the few nephropathies that has a
specific therapy. Currently, both a chaperone, migalastat, and a
recombinant enzyme, agalsidase, are approved for the treat-
ment of Fabry disease, in which mutations in the GLA gene lead
to absent or inactive lysosomal a-galactosidase-A.
Podocyturia is the urinary loss of podocytes. Since podocytes
are terminally differentiated cells that do not divide and have
limited replacement potential in adults, loss of podocytes in
urine is thought to contribute to progressive podocyte depletion
and CKD progression. More than a decade ago, the potential of
podocyturia to detect early kidney injury, preceding
pathological albuminuria, or to identify active disease versus
scar-related proteinuria, was already acknowledged [2].
However, the diverse techniques used to assess podocyturia
(microscopy of stained cells, proteomics-based assays or mRNA
quantification) have not yet been standardized to the point that
they may enter/be used in clinical practice [3–8]. Antibodies
against several podocyte proteins have been used to stain for
them in urine and different authors have reported increased
podocyturia in Fabry disease when assessed by podocalyxin
staining [5–8]. Both podocalyxin and synaptopodin are used to
identify podocytes in urine. However, few authors have stained
for both proteins, and when they have, they did not report
whether results differed depending on the marker used [9]. In
this issue of CKJ, Trimarchi et al. report that in Fabry
Received: 30.7.2018; Editorial decision: 30.7.2018
VC The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For permissions, please email: journals.permissions@oup.com.
49
Clinical Kidney Journal, 2019, vol. 12, no. 1, 49–52
doi: 10.1093/ckj/sfy081
Advance Access Publication Date: 5 October 2018
Editorial Comment
nephropathy, podocalyxin may be lost from detached urinary
podocytes before synaptopodin expression is lost [10]: all con-
trol urinary podocytes colocalized synaptopodin and podoca-
lyxin, whereas in Fabry patients, most podocytes only stained
for synaptopodin and no podocalyxin-positive/synaptopodin-
negative cells were observed. One practical consequence would
be that podocalyxin staining may underestimate podocyturia.
In this regard, Trimarchi et al. hypothesize that a decrease in
podocalyxin may be associated with less adhesiveness of cells
to the extracellular matrix, favouring detachment and urinary
excretion.
In Fabry disease, observations regarding the relationship of
podocyturia with albuminuria or glomerular filtration rate (GFR)
were not concordant [5–8]. Given the low number and heteroge-
neity of studied patients, this is not surprising. In this regard,
several dynamic processes may influence the association of
podocyturia with analytical evidence of kidney injury or pro-
gression. Thus, an increase in podocyturia appears to precede
the increase in albuminuria, but progressive loss of podocytes
and glomeruli reflected in decreasing GFR may, in turn, de-
crease podocyturia [11]. Alternatively, as suggested by
Trimarchi et al., phenotypic changes may influence urinary
podocyte quantification results when antibodies with different
specificities are used [10]. Although it was a cross-sectional
study, patients in whom urinary podocytes co-localized both
proteins had higher podocyturia and lower proteinuria. One po-
tential interpretation is that this represents an earlier stage of
the disease, in which the podocyte phenotype has not yet been
compromised, which is followed, when disease progresses, by
selective podocalyxin depletion [10]. However, alternative
explanations are possible. Podocalyxin-negative, synaptopodin-
positive cells may represent cells other than podocytes.
In this regard, according to the Protein Atlas, some anti-
synaptopodin antibodies may faintly stain tubular cells (https://
www.proteinatlas.org/ENSG00000171992-SYNPO/tissue/kidney#
img; accessed 17 July 2018), or the test for synaptopodin staining
may be more sensitive than the test for podocalyxin staining.
However, preservation over time of staining in stored urine
should not be an issue, since all samples were collected on site.
What needs to be done now? The hypothesis that podocalyxin
may be lost earlier than synaptopodin in injured Fabry podocytes
should be tested in renal biopsies from Fabry patients.
What might be the mechanisms underlying the early podo-
calyxin loss? Injured podocytes may lose or decrease the ex-
pression of podocyte-specific proteins. Podocalyxin is the major
sialoprotein of the glycocalyx of podocyte bodies and foot pro-
cesses and locates mainly to urinary surfaces, above the level of
slit diaphragms [12]. Synaptopodin is a cytoskeletal protein pre-
sent in the foot processes of podocytes, and its expression is
also markedly diminished in the kidneys under proteinuric con-
ditions [13]. Podocalyxin expression commences at the early S-
shaped body stage, and is required for the formation and main-
tenance of podocyte foot processes [14], whereas synaptopodin
appears later, coinciding with the formation of foot processes
and is restricted to the basal portion of the podocytes, where
foot processes form [15] (Figure 1A). Decreased glomerular
podocalyxin immunostaining has been reported in primary glo-
merulonephritides associated with nephrotic syndrome and in
diabetic nephropathy, although synaptopodin was not explored
[16, 17]. In more detailed studies, podocalyxin and synaptopodin
expression was preserved in non-sclerotic glomeruli form mini-
mal change disease and membranous nephropathy. By con-
trast, in idiopathic or HIV-associated collapsing focal segmental
glomerulosclerosis, 16% of the histologically unaffected glomer-
uli showed marked reduction of synaptopodin expression but
not of podocalyxin (Figure 1B) [15]. This is in contrast to the uri-
nary findings of Trimarchi et al. in Fabry disease (Figure 1C). As
an extracellular protein, podocalyxin may be targeted by extra-
cellular enzymes. This may change the antigenicity or disrupt
the protein and/or function. Indeed, podocyte injury may result
in desialylation of podocalyxin [18]. Different antibodies may
recognize different podocalyxin forms [19].
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FIGURE 1: Graphic representation of podocalyxin and synaptopodin. (A) Normal healthy podocytes. Note foot processes and podocalyxin presence in the urinary sur-
face, above the slit diaphragm that connects two adjacent foot processes. (B) Artistic rendition of the loss of synaptopodin with preservation of podocalyxin as de-
scribed for collapsing focal segmental glomerulosclerosis [15]. (C) Potential appearance of a Fabry podocyte pre-detachment. Artistic rendition based on Trimarchi et al.
findings in the urine of Fabry patients [10]. Note foot process effacement and loss of podocalyxin-containing glycocalyx.
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What might be the drivers of podocalyxin loss? The urine
podocalyxin/synaptopodin ratio was decreased in diabetic ne-
phropathy as compared with other glomerulonephritides [20].
This may mimic the urinary findings of Trimarchi et al. in Fabry
disease. Indeed, both nephropathies may be considered meta-
bolic proteinuric forms of progressive CKD. A high glucose con-
centration suppressed podocalyxin expression in cultured
podocytes, but synaptopodin was not studied [21]. Lyso-Gb3 is a
metabolite accumulated in Fabry disease that induces a podo-
cyte stress response similar to that induced by high glucose
concentrations [22, 23]. In addition, lyso-Gb3 increases CD80 ex-
pression in podocytes, a marker found both in Fabry kidney bi-
opsies and in the urine of Fabry patients [8]. This supports
studying the impact of lyso-Gb3 on podocalyxin expression.
Two characteristics of Fabry disease emphasize the potential
importance of podocyturia assessment. First, the natural history
is several decades long and the first clinical evidence of kidney
injury, which is usually microalbuminuria, may take decades to
develop. Secondly, by the time kidney injury becomes clinically
evident, irreversible lesions may have developed. In this regard,
the timing of therapy initiation is an important consideration,
given the high cost of therapy and the burden of intravenous ad-
ministration in the case of the agalsidase.
Reports that increased podocyturia may precede pathologi-
cal albuminuria in Fabry disease open the door to a non-
invasive assessment of early kidney injury that may eventually
be used to initiate therapy when there is no other indication.
Only further research will guide the choice of the podocyturia
assay that may eventually make it into clinical practice.
Although normalization of podocyturia by urinary creatinine is
the current standard, and may be useful to compare the same
patient over time, urinary creatinine depends mainly on muscle
mass and may vary up to 4-fold between individuals, potentially
resulting in similar (up to 4-fold) interindividual variations in
creatinuria-normalized podocyturia in different patients with
similar rates of podocyte loss. The lower muscle mass (and uri-
nary creatinine) in females may lead to higher urinary podocy-
te:creatinine ratios. Reproducible methods for widespread
implementation for podocyturia detection are still lacking, but
if podocyturia ever reaches the clinical routine, different thresh-
old levels should be defined for males and females.
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